

### **Listing of Claims**

1. (Canceled).
2. (Canceled).
3. (Canceled).
4. (Canceled).
5. (Canceled).
6. (Canceled).
7. (Canceled).
8. (Canceled).
9. (Currently amended) A method for reduction of plasma glucose concentrations ~~in diseases, disorders or conditions~~ in human or non-human mammals in need thereof, said method comprising the step of administration of a pharmaceutical composition to said human or said non-human mammals, wherein said pharmaceutical composition consists of, as active agent, (1) a glucose-lowering agent metformin in one of its pharmaceutically acceptable forms, and (2) a lipid-improving agent selected from non-glucose-lowering fibrates, wherein said human or non-human mammals in need thereof have diseases, disorders or conditions are selected from the group consisting of diabetes mellitus, hyperglycemia, impaired glucose-tolerance, insulin resistant syndrome, obesity, and pancreatitis where abnormality in plasma glucose levels or glucose metabolism is a component.

10. (Original) The method according to claim 9, wherein the administration is by means of oral, inhalation, sublingual, buccal, intranasal, rectal, intravenous, subcutaneous, intramuscular, and transdermal administration.
11. (Previously presented) The method of claim 13, wherein weight ratio of metformin or of its pharmaceutically acceptable form to gemfibrozil ranges from 1:0.5 to 1:2.
12. (Previously presented) The method of claim 9, wherein the non-glucose-lowering fibrate is selected from gemfibrozil and ciprofibrate.
13. (Previously presented) The method of claim 12, wherein the non-glucose-lowering fibrate is gemfibrozil.
14. (Previously presented) The method of claim 9, wherein the glucose-lowering agent and the lipid-improving agent are mixed together to form an admixture and the admixture is administered to the human or non-human mammals.